IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.394
EU - Europa 2.801
AS - Asia 1.908
SA - Sud America 215
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 10
Totale 8.360
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.349
CN - Cina 1.458
IE - Irlanda 865
RU - Federazione Russa 421
FI - Finlandia 356
SG - Singapore 290
UA - Ucraina 277
DE - Germania 266
IT - Italia 222
BR - Brasile 191
SE - Svezia 132
GB - Regno Unito 79
HK - Hong Kong 75
FR - Francia 43
CA - Canada 36
AT - Austria 34
RO - Romania 27
NL - Olanda 24
BE - Belgio 14
IN - India 13
AR - Argentina 9
AU - Australia 9
TR - Turchia 9
PL - Polonia 8
EU - Europa 7
AE - Emirati Arabi Uniti 6
BD - Bangladesh 6
CH - Svizzera 6
CO - Colombia 6
MU - Mauritius 6
MX - Messico 6
EG - Egitto 5
UZ - Uzbekistan 5
VN - Vietnam 5
JP - Giappone 4
LA - Repubblica Popolare Democratica del Laos 4
MA - Marocco 4
CZ - Repubblica Ceca 3
ES - Italia 3
GR - Grecia 3
IQ - Iraq 3
LT - Lituania 3
LV - Lettonia 3
PK - Pakistan 3
PY - Paraguay 3
RS - Serbia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CL - Cile 2
GE - Georgia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
PH - Filippine 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TM - Turkmenistan 2
VE - Venezuela 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
GA - Gabon 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KR - Corea 1
LK - Sri Lanka 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 8.360
Salva come PNG Salva come JPEG
Città #
Dublin 864
Chandler 643
Jacksonville 423
Nanjing 393
Ashburn 276
Boardman 259
Princeton 167
Nanchang 163
Lawrence 158
Beijing 139
Helsinki 136
Wilmington 121
Singapore 118
Shenyang 116
Changsha 111
Hebei 110
Medford 101
New York 97
Jiaxing 91
Ann Arbor 79
Hong Kong 74
Shanghai 72
Moscow 69
Tianjin 61
Hangzhou 58
Pavia 39
Milan 37
Los Angeles 34
Nuremberg 30
Toronto 30
Woodbridge 29
Norwalk 28
Seattle 27
Falkenstein 23
Timisoara 22
Washington 20
Vienna 16
Fairfield 15
São Paulo 15
Brussels 14
Jinan 13
Verona 12
Auburn Hills 10
Rome 10
The Dalles 10
Zhengzhou 10
Falls Church 9
Florence 9
Guangzhou 8
Munich 8
Ningbo 8
Frankfurt am Main 7
Pune 7
Rio de Janeiro 7
Des Moines 6
Taizhou 6
Curitiba 5
Monmouth Junction 5
Orange 5
Paris 5
Ribeirão Preto 5
Brasília 4
Cairo 4
Dearborn 4
Fuzhou 4
Gallarate 4
Reston 4
San Francisco 4
Shijiazhuang 4
São José do Rio Preto 4
Azzano San Paolo 3
Belgrade 3
Belo Horizonte 3
Bogotá 3
Brugherio 3
Campinas 3
Campo Grande 3
Canberra 3
Council Bluffs 3
Dallas 3
Dubai 3
Duque de Caxias 3
Düsseldorf 3
Fano 3
Fiesole 3
Houston 3
Kunming 3
London 3
Lugano 3
Porto Alegre 3
Prague 3
Redwood City 3
Saint Paul 3
San Luis Obispo 3
Santa Clara 3
Tappahannock 3
Tashkent 3
Viamão 3
Vientiane 3
Wayne 3
Totale 5.569
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 109
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 100
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 89
Blast phase of essential thrombocythemia: A single center study. 88
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 86
An insidious presentation of splenic marginal zone lymphoma 82
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 81
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 80
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 80
JAK2 (V617F) mutation in healthy individuals 78
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 77
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 76
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 76
Clinical significance of somatic mutation in unexplained blood cytopenia 75
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 73
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 73
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 72
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 72
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 71
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 70
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 69
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 69
Peripheral intraneutrophil diplococci in a case of meningococcemia. 69
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 69
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 68
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 68
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 68
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 67
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 67
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 67
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 65
Familial chronic myeloproliferative disorders: the state of the art 65
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 64
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 64
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 64
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 63
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 63
Cardiovascular events and intensity of treatment in polycythemia vera. 63
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 63
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 63
Role of the molecular staging and response in the management of follicular lymphoma patients 62
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 62
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 62
Allelic imbalance in CALR somatic mutagenesis 62
Clinical relevance of JAK2 (V617F) mutant allele burden 62
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 62
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 61
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 60
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 60
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 60
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 60
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 60
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 58
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 58
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 58
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 57
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 57
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 56
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 55
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 54
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 54
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 54
Improving survival trends in primary myelofibrosis: an international study. 54
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 54
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 53
Mutations and prognosis in primary myelofibrosis 53
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 53
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 53
Diagnosis and management of prefibrotic myelofibrosis. 53
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 53
Mutational status of myeloproliferative neoplasms. 52
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 52
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. 51
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 51
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib 51
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 50
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 50
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 50
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 50
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 49
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 49
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 49
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 48
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms 48
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 48
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene 47
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 47
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. 47
A journey through infectious risk associated with ruxolitinib. 47
Facing erythrocytosis: Results of an international physician survey. 47
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 46
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 46
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 46
Somatic mutations of calreticulin in myeloproliferative neoplasms 46
LNK mutations in familial myeloproliferative neoplasms. 46
Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). 45
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 44
Myelofibrotic transformation in essentialthrombocythemia. Author reply 44
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 44
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 44
Totale 6.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.022
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.022
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202045 0 0 0 0 0 0 0 0 0 0 41 4
2020/2021605 74 48 13 62 4 62 10 106 53 89 66 18
2021/2022692 9 4 23 11 17 38 6 38 33 38 115 360
2022/20232.087 222 118 21 135 204 169 1 100 989 13 87 28
2023/20241.049 119 170 55 69 96 297 27 66 10 22 76 42
2024/20251.763 66 208 72 61 56 120 198 204 641 114 23 0
Totale 8.745